Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma

Axicabtagene ciloleucel (axi-cel), an autologous anti-CD19 chimeric antigen receptor T -cell therapy, was approved for relapsed/refractory (R/R) large B -cell lymphoma (LBCL) based on the results from pivotal Cohorts 1+2 of ZUMA-1 (NCT02348216). ZUMA-1 was expanded to investigate safety management strategies aimed at reducing the incidence and severity of cytokine release syndrome (CRS) and neurologic events (NEs). Prospective safety expansion Cohort 5 evaluated the impact of debulking therapy, including rituximab-containing immunochemotherapy regimens and radiotherapy, in axi-cel-treated patients; the CRS and NE management strategy paralleled those in Cohorts 1+2. Among the 50 patients in Cohort 5 who received axi-cel, 40% received >= 3 prior lines of chemotherapy, and 40% had disease that progressed while on the most recent chemotherapy. Forty-eight patients (96%) received debulking therapy, 14 (28%) radiotherapy only, and 34 (71%) systemic immunochemotherapy. Median decrease in tumor burden (per sum of product of diameters of target lesions) relative to screening was 17.4% with R-ICE/RGDP, 4.3% with other debulking chemotherapies, and 6.3% with radiotherapy only. All patients were followed for >= 8 months. CRS was reported in 43 patients (86%), with 1 patient (2%) experiencing grade >= 3. NEs were reported in 28 patients (56%), with 6 (12%) experiencing grade >= 3. Cytopenias were the most frequent grade >= 3 adverse event (AE); 19 (38%) and 18 (36%) treated patients had any and grade >= 3 prolonged thrombocytopenia, respectively, and 25 (50%) and 24 (48%) patients had any and grade >= 3 prolonged neutropenia, respectively. Overall, patients who received debulking chemotherapy had higher incidences of serious treatment -emergent AEs than those who received radiotherapy only. At the 24 -month analysis, objective response rate was 72%, and complete response rate was 56%. Median duration of response, progression -free survival, and overall survival were 25.8, 3.1, and 20.6 months, respectively. These results from exploratory Cohort 5 demonstrate the feasibility of debulking prior to axi-cel, and together with current real -world evidence, suggest that debulking regimens may help minimize the frequency and severity of CRS and NEs in patients with R/R LBCL. The incidence of other AEs observed in Cohort 5 suggest the risk/benefit profile was not improved via the debulking regimens studied here.